PDS Biotechnology Management
Management criteria checks 4/4
PDS Biotechnology's CEO is Frank Bedu-Addo, appointed in Mar 2019, has a tenure of 7.33 years. total yearly compensation is $828.31K, comprised of 74.3% salary and 25.7% bonuses, including company stock and options. directly owns 1.24% of the company’s shares, worth $589.38K. The average tenure of the management team and the board of directors is 3.3 years and 7.3 years respectively.
Key information
Frank Bedu-Addo
Chief executive officer
US$828.3k
Total compensation
| CEO salary percentage | 74.29% |
| CEO tenure | 7.3yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
PDSB: Future Clinical Data And Capital Raises Will Drive Upside Potential
Analysts have revised the price target for PDS Biotechnology to $7.50 from $9.00, citing updated assumptions around very large revenue growth expectations, a higher projected profit margin, a lower future P/E multiple, and a modestly adjusted discount rate. What’s in the News for PDS Biotechnology PDS Biotechnology filed a US$50 million follow-on equity offering of common stock as an at-the-market program, providing a potential source of additional capital.
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$33m |
| Dec 31 2025 | US$828k | US$615k | -US$34m |
| Sep 30 2025 | n/a | n/a | -US$35m |
| Jun 30 2025 | n/a | n/a | -US$37m |
| Mar 31 2025 | n/a | n/a | -US$35m |
| Dec 31 2024 | US$2m | US$597k | -US$38m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$5m | US$580k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$2m | US$540k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$7m | US$475k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$815k | US$450k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$3m | US$356k | -US$7m |
Compensation vs Market: Frank's total compensation ($USD828.31K) is about average for companies of similar size in the US market ($USD659.85K).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Bedu-Addo (60 yo)
Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. Dr. Bedu-Addo was Chief Executive Officer of PDS...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$828.31k | 1.24% $ 589.4k | |
| Chief Operating Officer | 2.2yrs | US$673.63k | 0% $ 0 | |
| Chief Medical Officer | 2.5yrs | US$677.32k | 0% $ 0 | |
| Principal Financial & Accounting Officer and CFO | 2.6yrs | no data | 0% $ 0 | |
| Chief Scientific Officer | 7.3yrs | US$1.68m | 0.22% $ 105.4k | |
| Senior VP | 4.1yrs | no data | 0% $ 0 | |
| Controller | no data | no data | no data |
Experienced Management: PDSB's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$828.31k | 1.24% $ 589.4k | |
| Independent Director | 7.3yrs | US$89.06k | 0.11% $ 52.2k | |
| Independent Chairman | 7.3yrs | US$119.56k | 0.14% $ 67.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.4yrs | US$90.06k | 0.021% $ 10.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 6.3yrs | US$66.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chair of the Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: PDSB's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 08:02 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PDS Biotechnology Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |